{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:30:23Z","timestamp":1791599423764,"version":"4.3.4"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"USC\/Norris Comprehensive Cancer Center Women's Cancers Program"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.breast.2013.09.006","type":"journal-article","created":{"date-parts":[[2013,10,28]],"date-time":"2013-10-28T20:15:21Z","timestamp":1382991321000},"page":"2-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Co-targeting estrogen receptor and HER2 pathways in breast cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"Arjun","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2013.09.006_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with ampli\ufb01cation of the HER-2\/neu oncogene","volume":"23","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.breast.2013.09.006_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"New Engl J"},{"key":"10.1016\/j.breast.2013.09.006_bib3","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the ef\ufb01cacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Ef\ufb01cacy and safety of trastuzumab as a single agent in \ufb01rst-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib5","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.breast.2013.09.006_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2013.09.006_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(11)70033-X","article-title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","volume":"12","author":"Gianni","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib8","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.breast.2013.09.006_bib9","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2epositive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2013.09.006_bib11","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.1984.2.10.1102","article-title":"Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer","volume":"2","author":"Clark","year":"1984","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.breast.2013.09.006_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00666351","article-title":"DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients","volume":"199","author":"Wenger","year":"1993","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.09.006_bib13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrc3081","article-title":"Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells","volume":"11","author":"Tyson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.breast.2013.09.006_bib14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the ef\ufb01cacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2013.09.006_bib15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib16","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2007.12.9437","article-title":"Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, alone or in combination trial","volume":"26","author":"Dowsett","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2013.09.006_bib18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1634\/theoncologist.2012-0414","article-title":"First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER","volume":"18","author":"Tripathy","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2013.09.006_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.breast.2013.09.006_bib20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/bjc.1992.22","article-title":"Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer","volume":"65","author":"Wright","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2013.09.006_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0304-3835(94)90194-5","article-title":"ERBB2 ampli\ufb01cation is associated with tamoxifen resistance in steroid receptor positive breast cancer","volume":"81","author":"Borg","year":"1994","journal-title":"Cancer Lett"},{"issue":"7-8","key":"10.1016\/j.breast.2013.09.006_bib22","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/sj.bjc.6690196","article-title":"Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer","volume":"79","author":"Houston","year":"1999","journal-title":"Br J Cancer"},{"issue":"18","key":"10.1016\/j.breast.2013.09.006_bib23","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2001.19.18.3808","article-title":"Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and\/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial","volume":"19","author":"Ellis","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib24","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2005.04.3034","article-title":"Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole","volume":"24","author":"Ellis","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib25","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/bcr3324","article-title":"Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study","volume":"14","author":"Vaz-Luis","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2013.09.006_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.breast.2013.09.006_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF01961241","article-title":"Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu","volume":"24","author":"Benz","year":"1992","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.09.006_bib28","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djh166","article-title":"Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer","volume":"96","author":"Shou","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.09.006_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/er.2006-0045","article-title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance","volume":"29","author":"Arpino","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.breast.2013.09.006_bib30","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.breast.2013.09.006_bib31","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1210\/en.2005-0247","article-title":"Insulin-like growth factor-I receptor signaling in tamoxifen resistant breast cancer: a supporting role to the epidermal growth factor receptor","volume":"146","author":"Knowlden","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.breast.2013.09.006_bib32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1210\/er.2004-0018","article-title":"Transcriptional regulation by steroid receptor co-activator phosphorylation","volume":"26","author":"Wu","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.breast.2013.09.006_bib33","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.steroids.2012.07.019","article-title":"Estradiol receptors in breast cancer cells: associated co-factors as targets for new therapeutic approaches","volume":"77","author":"Renoir","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.breast.2013.09.006_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10549-007-9618-4","article-title":"Estrogen receptors outside the nucleus in breast cancer","volume":"108","author":"Levin","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.09.006_bib35","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the ef\ufb01cacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as \ufb01rst-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cncr.26162","article-title":"Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients","volume":"118","author":"Montemurro","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2013.09.006_bib37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","article-title":"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated ef\ufb01cacy and biomarker analyses","volume":"112","author":"Cameron","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.09.006_bib38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1634\/theoncologist.2009-0181","article-title":"Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: \ufb01nal survival analysis of a phase III randomized trial lapatinib plus capecitabine in women with HER-2-positive advanced breast","volume":"15","author":"Cameron","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2013.09.006_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2013.09.006_bib40","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2013.09.006_bib41","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib42","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO) :a randomized open-label, multi-centre phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2013.09.006_bib44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2013.09.006_bib45","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/bcr3384","article-title":"HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer","volume":"15","author":"Denkert","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2013.09.006_bib46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10549-006-9307-8","article-title":"The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers","volume":"102","author":"Marcom","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.09.006_bib47","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-Positive, hormone Receptor- Positive metastatic breast cancer: results from the randomized phase III TAnDEM study","volume":"27","author":"Kaufman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.breast.2011.07.006","article-title":"Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer \u2013 results of the eLEcTRA trial","volume":"21","author":"Huober","year":"2012","journal-title":"Breast"},{"key":"10.1016\/j.breast.2013.09.006_bib49","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor activity\u00a0of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.breast.2013.09.006_bib50","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2013.09.006_bib51","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1634\/theoncologist.2011-0461","article-title":"Lapatinib for advanced or metastatic breast cancer","volume":"17","author":"Opdam","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2013.09.006_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/0008-5472.18.65.1","article-title":"The dual ErbB1\/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer","volume":"65","author":"Chu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2013.09.006_bib53","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1634\/theoncologist.2009-0240","article-title":"Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer","volume":"15","author":"Schwartzberg","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2013.09.006_bib55","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/0008-5472.CAN-07-2707","article-title":"Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function","volume":"68","author":"Massarweh","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2013.09.006_bib56","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","article-title":"Overall survival bene\ufb01t with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: \ufb01nal results from the EGF104900 study","volume":"30","author":"Blackwell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib57","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1158\/1078-0432.CCR-10-1905","article-title":"Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2\/neu-overexpre ssing breast tumor xenografts","volume":"17","author":"Rimawi","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.breast.2013.09.006_bib58","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.2012.44.8027","article-title":"Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006","volume":"31","author":"Rimawi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib59","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/jnci\/djk151","article-title":"Treatment of human epidermal growth factor receptor 2eoverexpressing breast cancer xenografts with multiagent HER-targeted therapy","volume":"99","author":"Arpino","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.09.006_bib60","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1677\/ERC-07-0240","article-title":"ERBB2 in\ufb02uences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2","volume":"15","author":"Pancholi","year":"2008","journal-title":"Endocrine-related Cancer"},{"issue":"6","key":"10.1016\/j.breast.2013.09.006_bib61","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1078-0432.CCR-09-2282","article-title":"Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer","volume":"16","author":"Cristofanilli","year":"2010","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.breast.2013.09.006_bib62","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-10-1869","article-title":"Ge\ufb01tinib or placebo in combination with tamoxifen in patients with hormone receptorepositive metastatic breast cancer: a randomized phase II study","volume":"17","author":"Osborne","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2013.09.006_bib63","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/17446651.1.1.33","article-title":"Insulin-like growth factor-I receptor signaling and resistance in breast cancer","volume":"1","author":"Jones","year":"2006","journal-title":"Expert Rev Endocrin Metab"},{"issue":"13","key":"10.1016\/j.breast.2013.09.006_bib64","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/0008-5472.CAN-12-0684","article-title":"Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment","volume":"72","author":"Fagan","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.breast.2013.09.006_bib65","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1158\/0008-5472.CAN-11-1295","article-title":"A kinome-wide screen identi\ufb01es the insulin\/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer","volume":"71","author":"Fox","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2013.09.006_bib66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(13)70026-3","article-title":"Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial","volume":"14","author":"Robertson","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib67","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.breast.2013.09.006_bib68","article-title":"Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer","volume":"72","author":"Piccart","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2013.09.006_bib69","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptorepositive, human epidermal growth factor receptor 2enegative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib70","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2011.38.3331","article-title":"Randomized phase III placebo controlled trial of letrozole plus oral temsirolimus as \ufb01rst-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.09.006_bib71","article-title":"Characterization of the overall survival bene\ufb01t in ENCORE 301, a randomized placebo-controlled phase II study of exemestane with and without entinostat in ER\u00fe postmenopausal women with metastatic breast cancer","volume":"30","author":"Klein","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613002592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613002592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:31:07Z","timestamp":1760776267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977613002592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0960977613002592"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2013.09.006","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-targeting estrogen receptor and HER2 pathways in breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2013.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}